NCT01482195View on ClinicalTrials.gov

Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2019

Conditions
Retinal DiseaseRetinitis Pigmentosa
Interventions
BIOLOGICAL

Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus

The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.

Trial Locations (1)

11462

King Khaled Eye Specialist Hospital, Riyadh

All Listed Sponsors
collaborator

King Faisal Specialist Hospital & Research Center

OTHER

lead

King Khaled Eye Specialist Hospital

OTHER_GOV

NCT01482195 - Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK) | Biotech Hunter | Biotech Hunter